Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director departure
Appointed director
Skye Bioscience, Inc. (NMUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "AMENDMENT NO. 1 TO THE SKYE BIOSCIENCE, INC."
08/21/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURED CONVERTIBLE PROMISSORY NOTE",
"COMMON STOCK PURCHASE WARRANT SKYE BIOSCIENCE, INC.",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"SKYE BIOSCIENCE, INC. SECURED NOTE AND WARRANT PURCHASE AGREEMENT",
"INDEMNIFICATION AGREEMENT",
"Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody"
03/27/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "MASTER TRANSACTION AGREEMENT"
01/06/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "AMENDMENT NO. 5 MULTI DRAW CREDIT AGREEMENT"
12/16/2022 8-K Quarterly results
11/23/2022 8-K Quarterly results
10/03/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
12/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD with the Appointment of Life Sciences Executive Keith W. Ward, PhD"
10/15/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED",
"Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program Exclusive sponsored research agreement with endocannabinoid research pioneers"
09/28/2021 8-K Quarterly results
09/14/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/22/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Letter Agreement",
"Form of New Warrant"
02/03/2021 8-K Quarterly results
01/19/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Amendment to Articles of Incorporation",
"Press Release"
09/25/2020 8-K Quarterly results
08/12/2020 8-K Quarterly results
08/04/2020 8-K Quarterly results
06/22/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
04/29/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amended and Restated Multi-Draw Credit Agreement, by and between Emerald Bioscience, Inc. and Emerald Health Sciences, Inc. Sciences, Inc",
"Separation and Release Agreement, between Emerald Bioscience, Inc. and Doug Cesario"
12/20/2019 8-K Quarterly results
11/21/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Form of Warrant",
"Form of Securities Purchase Agreement, between the Company and certain purchasers set forth in the signature page thereto",
"Emerald Bioscience Announces $2.0 Million Registered Direct Offering"
11/20/2019 8-K Submission of Matters to a Vote of Security Holders
08/27/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Start-Up Agreement, by and between the Company and Novotech"
08/23/2019 8-K Other Events
08/08/2019 8-K Quarterly results
05/29/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Restated and Amended License Agreement, by and between the Company and UM",
"Restated and Amended License Agreement, by and between the Company and UM",
"Emerald Bioscience Secures “All Fields” Licenses for Cannabinoid Derivatives Developed by University of Mississippi Licenses permit Emerald to develop THC-prodrug and CBD-analog for any therapeutic indication by any route of administration for human and veterinary Use"
04/01/2019 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
03/25/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Certificate of Amendment to Articles of Incorporation",
"Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments Name change reflects company’s focus on advancing cannabinoid-based therapeutics as a member of the Emerald Group Company to trade on OTCQB under ticker EMBI at market open March 25, 2019"
03/04/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MASTER DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT This Master Development and Clinical Supply Agreement is made as of this 25th day of February 2019 , by and between Noramco, Inc., a Georgia corporation, with a place of business at [****] , and NEMUS Bioscience, Inc., a Nevada corporation, with a place of business at [****] . Client and Noramco may be referred to herein each as a “Party” or together as the “Parties”, as the context may require. RECITALS A. Client is a biopharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based therapeutics; B. Noramco is engaged in the business of manufacturing and selling active pharmaceutical; and C. Client and Noramco desire to enter into this Agreement to provide the terms and conditions upon which Noramco...",
"FORWARD LOOKING STATEMENTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy